Anti-tumor and antimetastatic activities of IL-12 were exploited in several preclinical models [83], but during clinical studies, IL-12 administration failed to elicit any sustained anti-tumor response because of several toxicities, adverse effects, and the increase in tumor immunosuppressive properties by IL-10 induction [84]. Here, IL10 is linked to neoplasm.